Background: Deficiency of the lysosomal enzyme galactosylcerebrosidase (GALC) causes Krabbe disease. Newborn screening for Krabbe disease is ongoing, but improved methods for follow-up analysis of screen-positive babies are needed to better advise families and to optimize treatment. We report a new assay for the enzymatic activity of GALC in lymphocytes.
Methods: T lymphocytes were isolated from venous blood by magnetic bead technology. The assay used a close structural analog of the natural substrate and LC-MS/MS to quantify the amount of product with the aid of a chemically identical internal standard.
Results: The analytical range of the assay (ratio of assay response for the QC high standard to that from all non-enzymatic-dependent processes) was 20-fold greater than that for the conventional radiometric GALC assay. The LC-MS/MS could distinguish cells that were null in GALC from those that contained traces of active enzyme (down to 0.3% of normal). There was a good correlation between the level of residual GALC activity in lymphocytes and the severity of Krabbe disease.
Conclusions: The new assay can measure small amounts of residual GALC activity in leukocytes with high accuracy compared to previous assays and can contribute, along with genotyping, biomarker analysis, and neurological imaging, a better plan for post-newborn screening follow-up for Krabbe disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533636 | PMC |
| http://dx.doi.org/10.1373/clinchem.2016.264952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measuring health-related quality of life in cardiovascular disease using a novel patient-centred and disease-specific patient-reported outcome measure.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Background: Assessment of health-related quality of life (HRQoL) in patients with cardiovascular disease (CVD) is impaired by limitations of current patient-reported outcome measures (PROMs). We developed the first cardiovascular disease (CVD) specific electronic PROM for which health items were derived by a fully patient-centered method. This paper reports on the measurement of HRQoL in CVD patients by a novel developed electronic patient-centred PROM based on a preference-based measurement model.
View Article and Find Full Text PDFAblation of lipocalin-2 reduces neuroinflammation in a mouse model of Krabbe disease.
Sci Rep
December 2024
Department of Biotechnical and Clinical Laboratory Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14214, USA.
Lipocalin-2 (LCN2) is an acute-phase secretory molecule significantly upregulated in various neuroinflammatory and demyelinating conditions. Krabbe disease (KD) is a neurodegenerative lysosomal disorder caused by a galactosylceramidase (GALC) deficiency, accumulating cytotoxic psychosine in nervous systems, and subsequent neuroinflammation. Here, we show that LCN2 is highly overexpressed in GALC-deficient astrocytes.
View Article and Find Full Text PDFA lipid nanoparticle-based oligodendrocyte-specific mRNA therapy.
Mol Ther Nucleic Acids
December 2024
Department of Therapeutics for Multiple System Atrophy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Article Synopsis
- The study highlights the challenge of delivering mRNA therapies effectively into oligodendrocytes, a type of brain cell, as traditional viral vectors aren't effective.
- Researchers utilized LUNAR lipid nanoparticles to achieve high efficiency and specificity in delivering mRNA to these cells, leveraging low-density lipoprotein receptors with the help of apoprotein E.
- A single dose of LUNAR-human galactosylceramidase mRNA significantly improved the health and survival of twitcher mice, a model for Krabbe disease, showcasing the potential of this method for treating neurological disorders related to oligodendrocytes.
Human iPSC-derived myelinating organoids and globoid cells to study Krabbe disease.
PLoS One
December 2024
Departments of Biochemistry and Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Article Synopsis
- - Krabbe disease (Kd) is caused by a deficiency in the enzyme GALC, leading to the accumulation of the lipid galactosylceramide (GalCer), which produces a toxic lipid called psychosine that damages myelinating cells and leads to demyelination.
- - Research using induced pluripotent stem cells (iPSCs) from Kd patients revealed that Kd myelinating organoids exhibit early myelination defects without affecting other cell types, while the microglia in these organoids show changes in response to GalCer feeding.
- - The findings suggest that while Kd model organoids don't show classic lysosomal dysfunction, they provide an essential platform for studying the mechanisms behind demyel
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!